Summary & Overview
HCPCS A9612: Injection, Fluorescein, 1 mg
HCPCS Level II code A9612 denotes a 1 mg injection of fluorescein, a diagnostic dye used to enhance visualization during ophthalmic examinations and select imaging procedures. Nationally, this code is relevant for outpatient diagnostic workflows where fluorescein angiography or other dye-enhanced imaging is performed, affecting billing, supply management, and clinical documentation practices. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what A9612 represents clinically and operationally, plus national payer coverage context and commonly reported modifiers. The publication summarizes benchmark pricing patterns and billing frequency where available, highlights relevant policy updates affecting dye and injectable diagnostic agents, and outlines coding considerations that can influence claims processing and reimbursement. The content is targeted at billing professionals, practice managers, and clinicians involved in diagnostic ophthalmology and outpatient imaging services who need a practical reference to the code, its use cases, and typical sites of service.
Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, and related codes; those items are noted as unavailable and are not included in the summary.
Billing Code Overview
HCPCS Level II code A9612 describes injection, fluorescein, 1 mg. This code represents a single-dose injectable diagnostic agent used to visualize vascular and tissue structures, most commonly in ophthalmic diagnostic procedures and certain imaging applications.
Service Type: Diagnostic injection
Typical Site of Service: Outpatient clinic or ambulatory surgical center, including ophthalmology offices and diagnostic imaging suites where fluorescein-enhanced examinations are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents to the ophthalmology clinic with acute onset of decreased vision and suspicion for retinal vascular pathology. The ophthalmologist recommends intravenous administration of fluorescein for fluorescein angiography to evaluate retinal and choroidal circulation. The patient is prepped in an outpatient clinic procedure room or ambulatory surgery center: informed consent is confirmed, allergy screen and IV access are established, and baseline vital signs are recorded. A measured dose of sodium fluorescein is drawn and administered as an intravenous bolus; serial fundus photographs and angiographic imaging are obtained over several minutes. Post-procedure monitoring for adverse reaction occurs for 15–30 minutes. Typical documentation includes indication (e.g., diabetic retinopathy, retinal vein occlusion, choroidal neovascularization), amount and route of fluorescein administered, lot number, and any immediate adverse events. Billing uses HCPCS Level II code A9612 for the injected fluorescein (1 mg unit) in conjunction with the imaging CPT codes and appropriate modifiers reflecting circumstance of service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / not used for CMS reporting | Rarely appended; included in systems that require a default modifier |